Emergency management and commonly encountered outpatient scenarios in patients with hyperkalemia

Mayo Clinic Proceedings

Volumn 82, Issue 12, 2007, Pages 1553-1561

  Sood, Manish M ^a   Sood, Amy R ^b   Richardson, Robert ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; BICARBONATE; CALCIUM SALT; CATION EXCHANGE RESIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HEPARIN; INSULIN; LAXATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYSTYRENE; POLYSTYRENESULFONATE CALCIUM; POTASSIUM; SALBUTAMOL; SPIRONOLACTONE;

ANXIETY; CARDIOVASCULAR RISK; CATION EXCHANGE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DRUG BINDING; DRUG DOSE COMPARISON; EMERGENCY CARE; FACTITIOUS DISEASE; FLUSHING; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; OUTPATIENT; PATIENT CARE; POTASSIUM BLOOD LEVEL; SHORT SURVEY; SIDE EFFECT; TACHYCARDIA; TREMOR; URINARY EXCRETION;

EID: 36749103694     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.12.1553     Document Type: Short Survey

References (39)

1. Acker CG, Johnson JP, Pavelsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158(8):917-924.
2. Rastegar A, Soleimani M. Hypokalaemia and hyperkalaemia. Postgrad Med J. 2001;77(914):759-764.
3. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J. 2006;33(1):40-47.
4. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18(6):721-729.
5. Webster A, Brady W, Morris F. Recognising signs of danger: ECG changes resulting from an abnormal serum potassium concentration. Emerg Med J. 2002;19(1):74-77.
6. Szerlip HM, Weiss J, Singer I. Profound hyperkalemia without electrocardiographic manifestations. Am J Kidney Dis. 1986;7(6):461-465.
7. Davey M, Caldicott D. Calcium salts in the management of hyperkalaemia [letter]. Emerg Med J. 2002;19(1):92-93.
8. Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med. 1996;28(4):440-441.
9. Mahoney BA, Smith WAD, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005;(2)CD003235:1-28.
10. Blumberg A, Weidmann P, Shaw S, Gnadinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85(4):507-512.
11. Advanced Life Support Group. Paediatric Life Support: The Practical Approach. 2nd ed. London, England: BMJ Publishing Group; 1997:254.
12. Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int. 1990;38(2):301-307.
13. Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? how safe? Chest. 1999;115(3):617-622.
14. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med. 1989;110(6):426-429.
15. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalemia, [editorial]. Nephrol Dial Transplant. 2003;18(11):2215-2218.
16. Allon M, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis. 1996;28(4):508-514.
17. Kim HJ. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron. 1996;72(3):476-482.
18. Weiner ID, Wingo CS. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9(8):1535-1543.
19. Rogers FB, Li SC. Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexelate) enemas in a critically ill patient: case report and review of the literature. J Trauma. 2001;51(2):395-397.
20. Mathialahan T, Maclennan KA, Sandle LN, Verbeke C, Sandle GI. Enhanced large intestinal potassium permeability in end-stage renal disease. J Pathol. 2005;206(1):46-51.
21. Cummings JH, Sladen GE, James OF, Sarner M, Misiewicz JJ. Laxative-induced diarrhoea: a continuing clinical problem. Br Med J. 1974;1(5907):537-541.
22. Ainley EJ, Winwood PJ, Begley JP. Measurement of serum electrolytes and phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. Dig Dis Sci. 2005;50(7):1319-1323.
23. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis. 2004;44(1):1-11.
24. Smellie WS. Spurious hyperkalaemia. BMJ. 2007;334(7595):693-695.
25. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75(12):793-795.
26. Pitt B, Zannad F, Remme W, et al, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717.
27. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551.
28. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297-303.
29. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41(2):211-214.
30. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148(6):971-978.
31. Saito M, Nakayama D, Takada M, Hirooka K, Yasmura Y. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candasartan cilexetil. J Clin Pharm Ther. 2006;31(6):535-540.
32. McCauley J, Murray J, Jordan M, Scantelbury V, Vivas C, Shapiro R. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol. 2002;22(4):347-351.
33. Nowicki M, Miszczak-Kuban J. Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron. 2002;91(2):222-227.
34. Isabel J, Champion JC. Junctional escape rhythm secondary to acute hyperkalemic renal failure in the setting of concurrent beta-blocker therapy. JAAPA. 2006;19(12):78.
35. Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed). 1985;291(6488):107-108.
36. Oster J, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98(6):575-586.
37. Orlando MP, Dillon ME, O'Dell MW. Heparin-induced hyperkalemia confirmed by drug rechallenge. Am J Phys Med Rehabil. 2000;79(1):93-96.
38. Sherman DS, Kass CL, Fish DN. Fludrocortisone for the treatment of heparin-induced hyperkalemia. Ann Pharmacother. 2000;34(5):606-610.
39. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management [editorial]. J Am Soc Nephrol. 1995;6(4):1134-1142.